Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02142894 · ClinicalTrials.gov registry record
Evaluation of the QuantiFERON-TB Test.
A clinical trial, sponsored by QIAGEN Gaithersburg.
- Completed
- Registry status
- 33
- Enrollment target
NCT02142894: Completed study, sponsored by QIAGEN Gaithersburg.
NCT02142894 is a clinical trial that has completed, run by QIAGEN Gaithersburg. The registered enrollment target is 33 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02142894 has completed, sponsored by QIAGEN Gaithersburg.
- COMPLETED
- Registry status
- 33 participants
- Enrollment target
Study Summary
To compare the results of the investigational test to the currently approved QuantiFERON-TB Gold In-Tube test.
Primary Outcome
To evaluate the clinical sensitivity of the CST001 assay in patients who have clinical signs/symptoms strongly indicating TB disease and who are receiving or have to start treatment for active TB, and whom Mycobacterium tuberculosis (MTB) is confirmed by bacteriological culture. Patients included in the testing either had a positive acid-fast bacillus (AFB) smear of have MTB in a specimen detected by nucleic acid amplification (NAA) of MTB complex Polymerase Chain Reaction (PCR), and who have re
Interventions
- DEVICE CST001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2014-05-27 |
| Est. Completion | 2016-03-28 |
What the finished NCT02142894 record still lists
NCT02142894 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 33 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which CST001 is the first listed.
NCT02142894 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02142894 about?
NCT02142894 is a clinical study titled "Evaluation of the QuantiFERON-TB Test.". To compare the results of the investigational test to the currently approved QuantiFERON-TB Gold In-Tube test.
What is the current status of trial NCT02142894?
This trial is currently completed. The enrollment target is 33 participants. The study started on 2014-05-27. Estimated completion is 2016-03-28.
What interventions are being tested in trial NCT02142894?
The interventions under investigation include: CST001 (DEVICE).
Who is sponsoring clinical trial NCT02142894?
This trial is sponsored by QIAGEN Gaithersburg, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI